Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Biochem Pharmacol. 2021 Nov 26;195:114859. doi: 10.1016/j.bcp.2021.114859

Figure 8. CCR5 antagonist treatment reduces vascular inflammatory genes and Nox1 expression.

Figure 8.

IL1β, TNFα, VCAM, and ICAM gene expression (A); Nox1, Nox2, and Nox4 gene expression (B) in non-ligated and ligated carotid arteries from animals treated or not with maraviroc for 7 days (20mg/kg/day, i.p) N=4. Data are presented as mean ± standard error of the mean (SEM). *P<0.05 vs non-ligated; #P<0.05 vs ligated + maraviroc.